These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15480433)

  • 41. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy.
    Frigola J; Muñoz M; Clark SJ; Moreno V; Capellà G; Peinado MA
    Oncogene; 2005 Nov; 24(49):7320-6. PubMed ID: 16007128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Methylation of the putative tumor suppressor gene, RASSF1A, in primary cervical tumors].
    Maliukova AV; Loginov VI; Khodyrev DS; Kadyrova EL; Pronina IV; Ivanova TA; Kiselev FL; Zabarovskiĭ NP; Braga EA
    Mol Biol (Mosk); 2004; 38(6):1005-13. PubMed ID: 15612586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
    Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
    BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
    Endoh H; Yatabe Y; Shimizu S; Tajima K; Kuwano H; Takahashi T; Mitsudomi T
    Int J Cancer; 2003 Aug; 106(1):45-51. PubMed ID: 12794755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural history of colorectal nonpolypoid adenomas: a prospective colonoscopic study and relation with cell kinetics and K-ras mutations.
    Watari J; Saitoh Y; Obara T; Fujiya M; Maemoto A; Ayabe T; Ashida T; Yokota K; Orii Y; Kohgo Y
    Am J Gastroenterol; 2002 Aug; 97(8):2109-15. PubMed ID: 12190185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of K-ras mutations with liver metastases from colorectal carcinoma.
    Tsunoda A; Iijima T; Tsunoda Y; Nakao K; Miyaki M; Kusano M
    Anticancer Res; 2004; 24(4):2471-6. PubMed ID: 15330200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.
    Ohshima J; Haruta M; Fujiwara Y; Watanabe N; Arai Y; Ariga T; Okita H; Koshinaga T; Oue T; Hinotsu S; Nakadate H; Horie H; Fukuzawa M; Kaneko Y
    Pediatr Blood Cancer; 2012 Sep; 59(3):499-505. PubMed ID: 22457227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic alterations in RASSF1A in human aberrant crypt foci.
    Greenspan EJ; Jablonski MA; Rajan TV; Levine J; Belinsky GS; Rosenberg DW
    Carcinogenesis; 2006 Jul; 27(7):1316-22. PubMed ID: 16513682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. β-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients.
    Chen SP; Wu CC; Huang SY; Kang JC; Chiu SC; Yang KL; Pang CY
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1277-81. PubMed ID: 23009572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. K-ras mutations in endometrial carcinomas with microsatellite instability.
    Lagarda H; Catasus L; Arguelles R; Matias-Guiu X; Prat J
    J Pathol; 2001 Feb; 193(2):193-9. PubMed ID: 11180166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The tumor suppressor RASSF1A in human carcinogenesis: an update.
    Dammann R; Schagdarsurengin U; Seidel C; Strunnikova M; Rastetter M; Baier K; Pfeifer GP
    Histol Histopathol; 2005 Apr; 20(2):645-63. PubMed ID: 15736067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.
    Zhang CY; Zhao YX; Xia RH; Han J; Wang BS; Tian Z; Wang LZ; Hu YH; Li J
    PLoS One; 2014; 9(10):e110159. PubMed ID: 25302792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.
    Wagner KJ; Cooper WN; Grundy RG; Caldwell G; Jones C; Wadey RB; Morton D; Schofield PN; Reik W; Latif F; Maher ER
    Oncogene; 2002 Oct; 21(47):7277-82. PubMed ID: 12370819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma.
    Wistuba II; Behrens C; Albores-Saavedra J; Delgado R; Lopez F; Gazdar AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3615-9. PubMed ID: 14506148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Instability of X chromosome methylation in aberrant crypt foci of the human colon.
    Sakurazawa N; Tanaka N; Onda M; Esumi H
    Cancer Res; 2000 Jun; 60(12):3165-9. PubMed ID: 10866306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
    Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
    Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.